Literature DB >> 18344973

Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia.

Takashi Torashima1, Chiho Koyama, Akira Iizuka, Kazuhiro Mitsumura, Kiyohiko Takayama, Shigeru Yanagi, Miho Oue, Haruyasu Yamaguchi, Hirokazu Hirai.   

Abstract

Polyglutamine disorders are inherited neurodegenerative diseases caused by the accumulation of expanded polyglutamine protein (polyQ). Previously, we identified a new guanosine triphosphatase, CRAG, which facilitates the degradation of polyQ aggregates through the ubiquitin-proteasome pathway in cultured cells. Because expression of CRAG decreases in the adult brain, a reduced level of CRAG could underlie the onset of polyglutamine diseases. To examine the potential of CRAG expression for treating polyglutamine diseases, we generated model mice expressing polyQ predominantly in Purkinje cells. The model mice showed poor dendritic arborization of Purkinje cells, a markedly atrophied cerebellum and severe ataxia. Lentivector-mediated expression of CRAG in Purkinje cells of model mice extensively cleared polyQ aggregates and re-activated dendritic differentiation, resulting in a striking rescue from ataxia. Our in vivo data substantiate previous cell-culture-based results and extend further the usefulness of targeted delivery of CRAG as a gene therapy for polyglutamine diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344973      PMCID: PMC2288764          DOI: 10.1038/embor.2008.31

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  14 in total

1.  Adenovirus-mediated expression of mutant DRPLA proteins with expanded polyglutamine stretches in neuronally differentiated PC12 cells. Preferential intranuclear aggregate formation and apoptosis.

Authors:  A Sato; T Shimohata; R Koide; H Takano; T Sato; M Oyake; S Igarashi; K Tanaka; T Inuzuka; H Nawa; S Tsuji
Journal:  Hum Mol Genet       Date:  1999-06       Impact factor: 6.150

Review 2.  Patterned Purkinje cell death in the cerebellum.

Authors:  Justyna R Sarna; Richard Hawkes
Journal:  Prog Neurobiol       Date:  2003-08       Impact factor: 11.685

3.  A promoter that drives transgene expression in cerebellar Purkinje and retinal bipolar neurons.

Authors:  J Oberdick; R J Smeyne; J R Mann; S Zackson; J I Morgan
Journal:  Science       Date:  1990-04-13       Impact factor: 47.728

4.  Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.

Authors:  T Yoshizawa; Y Yamagishi; N Koseki; J Goto; H Yoshida; F Shibasaki; S Shoji; I Kanazawa
Journal:  Hum Mol Genet       Date:  2000-01-01       Impact factor: 6.150

Review 5.  The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis.

Authors:  B T Koshy; H Y Zoghbi
Journal:  Brain Pathol       Date:  1997-07       Impact factor: 6.508

6.  A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.

Authors:  Daniel Goti; Scott M Katzen; Jesse Mez; Noam Kurtis; Jennifer Kiluk; Lea Ben-Haïem; Nancy A Jenkins; Neal G Copeland; Akira Kakizuka; Alan H Sharp; Christopher A Ross; Peter R Mouton; Veronica Colomer
Journal:  J Neurosci       Date:  2004-11-10       Impact factor: 6.167

7.  YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit.

Authors:  Cemal K Cemal; Christopher J Carroll; Lorraine Lawrence; Margaret B Lowrie; Piers Ruddle; Sahar Al-Mahdawi; Rosalind H M King; Mark A Pook; Clare Huxley; Susan Chamberlain
Journal:  Hum Mol Genet       Date:  2002-05-01       Impact factor: 6.150

8.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.

Authors:  Y Kawaguchi; T Okamoto; M Taniwaki; M Aizawa; M Inoue; S Katayama; H Kawakami; S Nakamura; M Nishimura; I Akiguchi
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

9.  RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.

Authors:  Haibin Xia; Qinwen Mao; Steven L Eliason; Scott Q Harper; Inês H Martins; Harry T Orr; Henry L Paulson; Linda Yang; Robert M Kotin; Beverly L Davidson
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

10.  Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.

Authors:  Ulrike Bichelmeier; Thorsten Schmidt; Jeannette Hübener; Jana Boy; Lukas Rüttiger; Karina Häbig; Sven Poths; Michael Bonin; Marlies Knipper; Werner J Schmidt; Johannes Wilbertz; Hartwig Wolburg; Franco Laccone; Olaf Riess
Journal:  J Neurosci       Date:  2007-07-11       Impact factor: 6.167

View more
  42 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  CRMP5-associated GTPase (CRAG) protein protects neuronal cells against cytotoxicity of expanded polyglutamine protein partially via c-Fos-dependent activator protein-1 activation.

Authors:  Shun Nagashima; Toshifumi Fukuda; Yuka Kubota; Ayumu Sugiura; Mitsuyoshi Nakao; Ryoko Inatome; Shigeru Yanagi
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

3.  High transgene expression by lentiviral vectors causes maldevelopment of Purkinje cells in vivo.

Authors:  Yusuke Sawada; Go Kajiwara; Akira Iizuka; Kiyohiko Takayama; Anton N Shuvaev; Chiho Koyama; Hirokazu Hirai
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

Review 4.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

5.  Longitudinal tracking of gait and balance impairments in cerebellar disease.

Authors:  Susanne M Morton; Ya-Weng Tseng; Kathleen M Zackowski; Jaclyn R Daline; Amy J Bastian
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

6.  Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells.

Authors:  Ayumu Konno; Anton N Shuvaev; Noriko Miyake; Koichi Miyake; Akira Iizuka; Serina Matsuura; Fathul Huda; Kazuhiro Nakamura; Shigeru Yanagi; Takashi Shimada; Hirokazu Hirai
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

Review 7.  Basic research on cerebellar gene therapy using lentiviral vectors.

Authors:  Hirokazu Hirai
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

Review 8.  Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).

Authors:  Veronica F Colomer Gould
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

9.  Kv3.3 channels harbouring a mutation of spinocerebellar ataxia type 13 alter excitability and induce cell death in cultured cerebellar Purkinje cells.

Authors:  Tomohiko Irie; Yasunori Matsuzaki; Yuko Sekino; Hirokazu Hirai
Journal:  J Physiol       Date:  2013-11-11       Impact factor: 5.182

10.  Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Mariana Conceição; Nicole Déglon; Luís Pereira de Almeida
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.